bupivacaine hydrochloride; epinephrine bitartrate
BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE (bupivacaine hydrochloride; epinephrine bitartrate) by Pfizer is impulses, presumably by increasing the threshold for electrical excitation in the nerve, by slowing the propagation of the nerve impulse, and by reducing the rate of rise of the action potential. Approved for regional anesthesia, analgesia for surgery, dental and 4 more indications. First approved in 1983.
Drug data last refreshed 4h ago · AI intelligence enriched 1w ago
Bupivacaine hydrochloride combined with epinephrine bitartrate is a long-acting local anesthetic injectable used for regional anesthesia and analgesia across surgical, dental, and obstetrical procedures. It works by blocking nerve impulse generation and conduction, with epinephrine added as a vasoconstrictor to slow systemic absorption and prolong anesthetic duration.
Product approaching loss of exclusivity with moderate competitive pressure (30/100), indicating potential team consolidation and transition to generic defense strategies.
impulses, presumably by increasing the threshold for electrical excitation in the nerve, by slowing the propagation of the nerve impulse, and by reducing the rate of rise of the action potential. In general, the progression of anesthesia is related to the diameter, myelination, and conduction…
Worked on BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moThis product represents a mature, LOE-approaching injectable asset with limited linked job volume, indicating smaller commercial teams and niche specialization. Career opportunity is defensive and operational—suited for professionals focused on generic transition strategies, hospital/surgical center relationships, and lifecycle extension rather than new market expansion.